Clinical Trial

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-06-27; most recent amendment 2026-02-27.
Trial Details
NCT Number NCT07046559
Lead Sponsor Eli Lilly and Company
Conditions Healthy, Cancer
Enrollment 104 participants
Start Date 2025-05-13
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-03